Handa Pharmaceuticals, Inc. (TPEX:6620)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
82.10
+0.50 (0.61%)
Apr 2, 2025, 1:55 PM CST
-49.32%
Market Cap 11.52B
Revenue (ttm) 972.97M
Net Income (ttm) 452.32M
Shares Out 141.20M
EPS (ttm) 3.24
PE Ratio 25.17
Forward PE 5.11
Dividend 1.00 (1.23%)
Ex-Dividend Date n/a
Volume 107,491
Average Volume 450,871
Open 82.70
Previous Close 81.60
Day's Range 80.70 - 82.70
52-Week Range 49.90 - 173.50
Beta 1.26
RSI 40.90
Earnings Date Apr 2, 2025

About Handa Pharmaceuticals

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; HND-033 and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis and h... [Read more]

Sector Healthcare
Founded 2014
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6620
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.